Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M23-703 Lutikizumab vs Adalimumab in Moderately to Severely Active Ulcerative Colitis
jRCT2031240064Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised trial of lutikizumab in autoimmune colitis (6 arms), sponsored by AbbVie Inc. Started Aug 2024; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031240064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240064.